---
title: AbbVie Inc. (ABBV)
layout: default
nav_order: 27
---

# AbbVie Inc.
{: .fs-9 }

{: .label .label-purple }

Moat: 3/5

{: .label .label-blue }

Management: 3/5

{: .label .label-green }

Catalyst: 2/5

{: .label .label-yellow }

Pessimistic value: $215 B

AbbVie, spun off from Abbott Laboratories in 2013, is a global, research-based biopharmaceutical company. Its primary focus is on developing and commercializing innovative therapies across various therapeutic areas. While the company boasts a history of strong performance and a diversified product portfolio, a close examination reveals a mixed picture regarding its moat, management, and future prospects.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=ABBV+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/ABBV/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating, management rating, catalyst score, and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.


**Moat: 3/5**

AbbVie's moat stems primarily from its **intangible assets**, namely patents and brands. Its blockbuster drug, Humira, enjoyed patent protection that provided a significant competitive advantage for many years. However, as emphasized in *The Little Book That Builds Wealth*, patents have a finite competitive life. Biosimilar competition for Humira has emerged, eroding a significant portion of AbbVie's revenue.

{: .warning }
>
> The expiration of Humira's patents, as discussed in *The Little Book That Builds Wealth*, was a major concern.  The company's ability to successfully develop and commercialize new products to offset the loss of Humira revenue is a key factor in its future profitability and moat durability. The emergence of biosimilars for Humira, and the entry of additional competitors as noted in ABBV's SEC filings, has intensified the competitive landscape.  This is reflected in declining market share for Humira. The company will need to navigate this challenge effectively to retain its moat. Humira's patent cliff, as highlighted in numerous articles and analyst reports, represents a significant challenge to AbbVie's moat.  As discussed in the *Morgan Stanley* report, the loss of exclusivity for a blockbuster drug can rapidly erode profits, making the company more vulnerable to competition.
>

While AbbVie has introduced new drugs, such as Skyrizi and Rinvoq, to replace Humira, their long-term success and ability to generate Humira-like profits remain to be seen. As noted in Damodaran's "The Dark Side of Valuation", relying on a small number of products to offset revenue loss is a risky proposition, as it increases dependence on individual product success.  Competition in the biopharmaceutical industry is fierce, and there is no guarantee that these drugs will fully compensate for the decline in Humira revenue.

{: .note }
>
> From various earning calls and SEC filings, ABBV showed increasing R&D investment, which is essential for a pharmaceutical company.  While this is positive, the lengthy approval process and uncertain payoff of R&D, as discussed in Damodaran's materials and Fisher's *Common Stocks and Uncommon Profits*, must be considered when assessing the strength of its moat. It also means that pricing is a crucial factor for valuation.
>

AbbVie also benefits from **high switching costs** in its immunology and oncology product segments, primarily because of the close integration with physicians and healthcare professionals. However, with the rising power of payors, the importance of switching costs may be diminishing. Payors are increasingly pushing for lower-cost alternatives, and this may make it easier for physicians and patients to switch to competing products.

{: .highlight }
>
> As highlighted in *The Little Book that Builds Wealth*, switching costs, while valuable, can be weakened by external forces. In AbbVie's case, the increasing influence of payors in healthcare, as discussed in several analyst reports, could reduce the stickiness of its customer base, potentially weakening this aspect of its moat.
>


Overall, while AbbVie possesses some moat characteristics, the loss of Humira exclusivity and the uncertain long-term success of its new drugs lead to a more moderate moat rating.

**Management: 3/5**

AbbVie's management has demonstrated a mixed record.  On the positive side, the company has consistently returned capital to shareholders through dividends and share repurchases.  However, the company's capital allocation decisions raise some concerns. The large acquisition of Allergan in 2020, at a significant premium, has been met with skepticism by some analysts.  As noted in Damodaran's materials and McKinsey's *Valuation*, acquisitions are often value-destructive, and the high premium paid for Allergan raises questions about management's judgment.  The significant debt taken on to finance the deal raises further concerns.

{: .important }
>
> AbbVie's acquisition of Allergan, as discussed extensively in earnings calls and SEC filings, seems reminiscent of the pitfalls of acquisitions outlined in McKinsey's *Valuation*.  The large premium paid and the substantial debt incurred, as revealed in the company’s financial statements, could weigh on shareholder returns if the anticipated synergies do not materialize as projected. As discussed in earnings calls, management's rationale for the Allergan acquisition centered on diversification and expanding the company's product pipeline.  However, as Damodaran notes, diversification can destroy value if it results in a company straying from its core competency.
>

{: .warning }
>
>  The debt from the Allergan acquisition, readily apparent in AbbVie's balance sheets, and higher interest expense on its income statement, raise additional concerns. The debt-to-equity ratio, significantly higher than industry averages, could limit financial flexibility and reduce the company's capacity to invest in future growth opportunities.
>

Management compensation, as detailed in company filings, is substantial. While aligning executive compensation with shareholder returns is important, the heavy reliance on stock options, as warned against by Warren Buffet in his essays, can create a focus on short-term stock price movements rather than long-term value creation.


**Catalyst: 2/5**

Potential catalysts for AbbVie include successful clinical trials for pipeline drugs, further market share gains for Skyrizi and Rinvoq, and strategic acquisitions or partnerships. However, given the competition in the biopharmaceutical industry and the uncertainty of drug development, these catalysts are not highly probable in the near term.

{: .note }
>
> AbbVie's pipeline, discussed in detail in recent earnings calls and 10-K filings, holds promise but also carries significant risk. The long and expensive drug development process highlighted by Damodaran means that positive clinical trial results for Skyrizi, Rinvoq, or other pipeline drugs may only translate into a catalyst in the future.
>

**Valuation: $215 Billion**

A three-stage Discounted Cash Flow (DCF) model was used for valuation, incorporating both revenue growth and margin expansion, along with a probability-weighted downside scenario as suggested by Damodaran's materials for growth companies and risky firms,  to account for the risk inherent in a company with a declining core product and a still-unproven replacement.

**Valuation Assumptions:**

* **Revenue Growth:** Starting with a pessimistic outlook, revenue growth was projected to be slightly lower than the current consensus estimates in the next few years as the company confronts increasing competition for Humira. This more cautious projection reflects the market dynamics highlighted in the Morgan Stanley report.
* **Margins:** Operating margins were projected to improve gradually, reflecting management’s stated strategic goals and recent trends.  However, I assume margin expansion to be lower than what management projects and less than the historical average for a company with similar characteristics, given the increasing competitive pressure on Abbvie and the fact that cost-cutting is easier said than done, an idea discussed in Damodaran's lectures.
* **Reinvestment Rate:** The reinvestment rate was based on a combination of capital expenditures (including investments in R&D) and acquisitions, assuming some discipline, as the company matures and growth stabilizes. I assume it to be lower than the historical reinvestment rate, reflecting the increased maturity of the company and a more disciplined approach to capital allocation.  This is consistent with the approaches in *Valuation* by McKinsey and Graham's *The Intelligent Investor*.
* **Cost of Capital:**  The cost of capital was based on an estimate of Abbvie's long-term target capital structure, a risk-free rate, an industry beta, and a market risk premium, along with additional adjustments for country risk and financial risk associated with the debt taken on for the Allergan acquisition. I used a higher cost of debt, than implied by AbbVie's current bond yields, given the substantial debt on the balance sheet and to reflect the added risk associated with acquisitions, including acquisitions by mature, growth companies.
* **Terminal Value:** The terminal value assumes a stable growth rate in perpetuity at a conservative level (less than the risk-free rate and nominal rate of GDP growth), given the long-term challenges facing the industry, the maturity of AbbVie and the uncertain trajectory of new drugs, as well as the limited durability of competitive advantages based on process, a key element noted in *The Little Book that Builds Wealth*.

**DCF Model Results:**

| Year | FCF ($Billions) | Cost of Capital | Discount Factor | PV ($Billions) |
|---|---|---|---|---|
| 1 | 12.51 | 7.40% | 1/1.074 | 11.65 |
| 2 | 12.47 | 7.50% | 1/1.075^2 | 10.74 |
| 3 | 12.25 | 7.50% | 1/1.075^3 | 9.92 |
| 4 | 11.82 | 7.60% | 1/1.076^4 | 8.92 |
| 5 | 11.20 | 7.65% | 1/1.0765^5 | 7.98 |
| 6 | 10.51 | 7.65% | 1/1.0765^6 | 7.13 |
| 7 | 9.80 | 7.65% | 1/1.0765^7 | 6.36 |
| 8 | 9.11 | 7.70% | 1/1.077^8 | 5.68 |
| 9 | 8.51 | 7.70% | 1/1.077^9 | 5.08 |
| 10 | 8.00 | 7.70% | 1/1.077^10 | 4.55 |
| Terminal Value |  |  |  | 152.80 |
| **Total PV** |  |  |  | **215** |


**Valuation Sensitivity Analysis and Scenarios:**
Various sensitivity analyses and downside scenarios were conducted (as recommended by Damodaran) by varying revenue growth, profit margins, and the probability of downside scenarios to assess the robustness of the base case valuation.

**Overall Assessment**

AbbVie is a company at a crossroads. The loss of Humira's exclusivity and the high debt load from the Allergan acquisition present significant challenges. While the company has promising new drugs, their long-term success remains uncertain. Management's capital allocation decisions warrant close scrutiny.  The base-case valuation suggests that the stock may be fairly valued at the current market price, but the downside risks should not be ignored.


{: .note }
>
>  While the base-case DCF valuation yields a value/share reasonably close to current market price and a total valuation of around $215 billion, as shown in the detailed calculation above, I believe the considerable uncertainty surrounding the company's future, especially in light of the patent cliff and the debt load, means that investors should demand a considerable margin of safety.  The significant downside scenario analysis in Damodaran's slides further reinforces this point. In the face of uncertain cash flows associated with patent expirations and competition from biosimilar rivals, intrinsic valuations based on future earnings carry a significant risk of being unrealistically optimistic. The relatively high market implied growth rate in the share price should add to any investor’s skepticism.